Acute Renal Failure Trial Network (ATN) Study
Completed · Phase 3 · NCT00076219
Conditions: Acute Renal Failure
At a glance
- Research payments reported, 2025
- $100,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,124
About the trial
- Sponsor
- US Department of Veterans Affairs (with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK))
- Tested
- renal replacement therapy (procedure)
- Dates
- Started 2003-10; completion 2008-07
- Results posted
- Yes
This is a multi-center, prospective, randomized, parallel-group trial of an intensive strategy vs conventional strategy of renal replacement therapy for the treatment of acute renal failure secondary to acute tubular necrosis in critically ill patients. The primary hypothesis is that the intensive strategy will reduce 60-day all cause mortality by 10% compared to the conventional strategy - i.e.,a reduction from 55% in the conventional arm to 45% in the intensive arm. Secondary outcomes are 60-day in-hospital all-cause mortality, 1-year all cause mortality, and recovery of renal function by day 28. The study will recruit 1164 patients over a period of 3 years, 8 months and each patient wi…
From ClinicalTrials.gov, last updated 2013-08-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Vantive US Healthcare LLC reported $100,000 in research payments for this study in 2025 (1 payments).
Products named: Renal - Crrt
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Pittsburgh $100,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.